Latest Breaking News On - Paul clozel - Page 10 : comparemela.com

Idorsia Pharmaceuticals Ltd: Health Canada approves QUVIVIQ (daridorexant) for the management of adult patients with insomnia

QUVIVIQ is indicated for the management of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.Idorsia Canada - led by General Manager Ron Morcos - aims

Switzerland generalUnited statesUnited kingdomGreat britainAndrewc weissJ clin pharmacolSanta monicaJean paul clozelRon morcosSwiss exchangeHead of investor relations corporate communicationsDrug administrationEuropean commission decision reliance procedureIdorsia pharmaceuticals ltdHealth canadaInternational study

Idorsia Pharmaceuticals Ltd: Idorsia announces financial results for the first quarter 2023 - QUVIVIQ now the leading branded insomnia medicine in the commercial market in the US

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - April 25, 2023 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2023. Commercial highlights QUVIVIQ

United statesSwitzerland generalUnited kingdomGreat britainMesse baselNeurocrine biosciencesAndrewc weissSchweizerisches handelsamtsblattSimon joseJean paul clozelHead of investor relations corporate communicationsRegulatory agencyCompany annualMochida pharmaceutical co ltdIdorsia ltdDay center

Idorsia Shares Evidence in Citizen Petition to De-Schedule DORA Class Insomnia Drugs

The petition with the US DEA is aiming to remove dual orexin receptor antagonist medications from the Controlled Substances Act due to negligible potential for abuse.

United statesVaughn mccallJean paul clozelHealth behavior at augusta universityDrug administrationIdorsia pharmaceuticalsDepartment of psychiatryDrug enforcement administrationCitizen petitionPaul clozelChief executive officerControlled substancesControlled substances actCase distinguished chairHealth behaviorAugusta university

Idorsia Pharmaceuticals Ltd: On World Sleep Day Idorsia highlights the publication of a global study on the economic and societal impact of chronic insomnia disorder

Chronic insomnia disorder (CID) is a persistent medical condition that prevents sufferers from getting restorative sleep1-3; research on wider societal and indirect economic costs associated with CID have

United statesSwitzerland generalUnited kingdomDennis riedlAndrewc weissJean paul clozelYerushalmie troxelSanta monicaMarco hafnerAmerican psychiatric associationInternational classification of sleep disordersWorld sleep societyHead of investor relations corporate communicationsUniversity of freiburgAmerican academy of sleep medicineUniversity of zurich

On World Sleep Day Idorsia highlights the publication of a global study on the economic and societal impact of chronic insomnia disorder

On World Sleep Day Idorsia highlights the publication of a global study on the economic and societal impact of chronic insomnia disorder
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSwitzerland generalUnited kingdomMarco hafnermarco hafnerJean paul clozelYerushalmie troxelSanta monicaAndrewc weissseniorMarco hafnerAmerican psychiatric associationWorld sleep societyInternational classification of sleep disordersUniversity of freiburgAmerican academy of sleep medicineInternational studytheUniversity of zurich